SCHEMBL758898

SCHEMBL758898

CC(=O)c1coc(Cc2ccc(F)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.42
KLKB1 P03952 3/20 0.39
DAGLA Q9Y4D2 1/20 0.39
HDAC1 Q13547 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
S1PR1 P21453 1/20 0.38
S1PR3 Q99500 1/20 0.38
TP53 P04637 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAOB P27338 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
RIPK1 Q13546 1/20 0.36
PDE4B Q07343 1/20 0.36
CACNA1G O43497 1/20 0.36
CACNA1H O95180 1/20 0.36
CACNA1I Q9P0X4 1/20 0.36
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27588398 0.85 NPSR1 (0.40) NPSR1KLKB1HDAC1HDAC8HDAC6
SCHEMBL21333174 0.84 DAGLA (0.52) KLKB1DAGLAKMT2AMAPTRIPK1
Hydrochloric Acid SCHEMBL17205234 0.84 GRM2 (0.42) NPSR1KLKB1S1PR1S1PR3
SCHEMBL754523 0.82 ALDH1A1 (0.46) NPSR1KLKB1KMT2AMAPTNPC1
SCHEMBL2486131 0.79 KLKB1 (0.49) NPSR1KLKB1HDAC1HDAC8HDAC6
SCHEMBL754810 0.76 CA12 (0.39) NPSR1KLKB1HDAC1HDAC8HDAC6
SCHEMBL754811 0.76 CA12 (0.39) NPSR1KLKB1HDAC1HDAC8HDAC6
SCHEMBL19871354 0.73 FPR2 (0.40) DAGLAHDAC6S1PR1
SCHEMBL1166830 0.73 FPR2 (0.42) DAGLAHDAC6
SCHEMBL2222487 0.73 HDAC1 (0.68) HDAC1HDAC8HDAC6KMT2APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2266958-B1 Antiviral agent SHIONOGI & CO (JP) 2017-03-15 EP disclosed
US-9572813-B2 Antiviral agent SHIONOGI & CO., LTD. (JP) 2017-02-21 US disclosed
EP-3042894-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2016-07-13 EP disclosed
US-20150202208-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2015-07-23 US disclosed
EP-1422218-B1 ANTIVIRAL AGENT SHIONOGI & CO (JP) 2012-03-21 EP disclosed
EP-2181985-B1 Antiviral Agent SHIONOGI & CO (JP) 2011-10-26 EP disclosed
EP-2266958-A1 Antiviral agent SHIONOGI & CO., LTD. (JP) 2010-12-29 EP disclosed
EP-2181985-A1 Antiviral Agent SHIONOGI & CO., LTD. (JP) 2010-05-05 EP disclosed
US-20040229909-A1 Antiviral agent SHIONOGI & CO., LTD. (JP) 2004-11-18 US disclosed
EP-1422218-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2004-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229909-A1 Antiviral agent ZC3HAV1, ZC3HAV1L, DUT NPSR1 4178/4885KLKB1 4508/4885DAGLA 3725/4885
US-20150202208-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI NPSR1 4131/4885KLKB1 4451/4885DAGLA 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.